Characterization of gene therapy products and the impact of manufacturing changes on product comparability

Area of Science:

• Biologics and Gene Therapy
• Regulatory Science
• Product Manufacturing

Background:

• Gene therapy products are novel and complex, necessitating rigorous safety evaluations.
• Manufacturing changes require assessment of the final product and all components.
• Regulatory compliance with current Good Manufacturing Practices (cGMPs) is essential.

Purpose of the Study:

• To highlight the importance of early and comprehensive product characterization in gene therapy development.
• To explain the stepwise approach to characterization and cGMP compliance.
• To underscore the necessity of understanding the manufacturing process for assessing change impacts.

Main Methods:

• Implementing a stepwise approach to product characterization from early development through licensing.
• Assessing not only the final formulated product but also all manufacturing components.
• Characterizing the product early to understand the manufacturing process.

Main Results:

• Early product characterization is critical for determining the impact of manufacturing processes and changes.
• A thorough understanding of the manufacturing process is necessary for demonstrating product comparability.
• A stepwise approach to characterization and cGMP compliance is employed by CBER.

Conclusions:

• Comprehensive product characterization early in development is vital for gene therapy safety and regulatory approval.
• Understanding the manufacturing process is key to assessing the impact of any changes.
• Demonstrating product comparability relies on robust characterization and process understanding.